select semaglutide trial Novo's obesity drug cuts risk of heart disease in study The SELECT Trial - A

Low-dose formulations of Semaglutide examined in this review paper reduce the incidence of major adverse cardiovascular events and death in overweight and/or diabetic individuals

Regulatory approval of new biosimilars requires an extensive comparability exercise against established and marketed reference products as it must include quality and clinical studies to demonstrate a high percentage of similarity in both terms of structure and function

You only move forward when the science says it's right for you

However, with no real definition or criteria to determine what exactly superfoods are, they have caused quite a bit of confusion for consumers